The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase

Background: Ceftazidime-avibactam was approved by the FDA to treat infections caused by Enterobacterales carrying <i>bla</i><sub>KPC-2</sub>. However, variants of KPC-2 with amino acid substitutions at position 179 have emerged and confer resistance to ceftazidime-avibactam....

Full description

Bibliographic Details
Main Authors: Krisztina M. Papp-Wallace, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Joseph D. Rutter, Elise T. Zeiser, Katherine Young, Robert A. Bonomo
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Antibiotics
Subjects:
KPC-2
carbapenemase
diazabicyclooctane
beta-lactam
beta-lactamase
relebactam
Online Access:https://www.mdpi.com/2079-6382/12/5/892

Internet

https://www.mdpi.com/2079-6382/12/5/892

Similar Items